Nasdaq:US$14.14 (+0.48) | HKEX:HK$22.30 (+0.10) | AIM:£2.30 (+0)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Management
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Careers
About Us
Overview
Corporate Information
Board of Directors
Management
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Careers
News & Presentations
Hutchmed
| News & Presentations
News & Press Releases
9 Aug 2022
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004
Read more
8 Aug 2022
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
Read more
8 Aug 2022
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial
Read more
1 Aug 2022
HUTCHMED Reports 2022 Interim Results and Provides Business Updates
Read more
Scientific Publications
6 Jun 2022
ASCO2022: Surufatinib in US Patients with Soft Tissue Sarcoma
Read more
6 Jun 2022
ASCO2022: A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs
Read more
12 Dec 2021
ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.
Read more
3 Nov 2021
NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors
Read more
Mailing List Sign-up
If you would like to be kept up to date with the latest news of HUTCHMED, please sign up to our mailing list . We will deliver the relevant material directly to your email box as soon as it becomes available online.